Table 2.
Regression models for receiving medication at different time points after first ischemic stroke. Patients with no pre-existing dementia are the reference category
| Model 1 | Model 2 | Model 3 | ||
| Antiplatelets | 1.28 (1.11–1.48)*** | 1.41 (1.21–1.64)*** | 1.23 (1.02–1.48)* | |
| in AF | 2.22 (1.80–2.75)*** | 2.02 (1.62–2.51)*** | 1.56 (1.21–2.01)*** | |
| At discharge | in non-AF | 0.80 (0.63–1.03) | 1.07 (0.83–1.39) | 0.99 (0.75–1.33) |
| BPLM | 0.61 (0.53–0.70)*** | 0.66 (0.57–0.76)*** | 0.57 (0.49–0.67)*** | |
| Statins | 0.44 (0.39–0.50)*** | 0.57 (0.49–0.65)*** | 0.57 (0.50–0.66)*** | |
| Anticoagulants in AF | 0.39 (0.30–0.49)*** | 0.48 (0.37–0.62)*** | 0.41 (0.32–0.53)*** | |
| Antiplatelets | 1.67 (1.43–1.94)*** | 1.61 (1.38–1.89)*** | 1.48 (1.24–1.78)*** | |
| in AF | 3.34 (2.55–4.38)*** | 2.95 (2.24–3.89)*** | 2.43 (1.76–3.35)*** | |
| 1-year post-stroke | in non-AF | 1.30 (1.06–1.60)* | 1.23 (1.00–1.53) | 1.18 (0.94–1.49) |
| BPLM | 0.68 (0.57–0.80)*** | 0.71 (0.60–0.84)*** | 0.59 (0.50–0.70)*** | |
| Statins | 0.56 (0.48–0.65)*** | 0.65 (0.56–0.76)*** | 0.65 (0.55–0.76)*** | |
| Anticoagulants in AF | 0.42 (0.31–0.55)*** | 0.47 (0.35–0.62)*** | 0.51 (0.38–0.68)*** | |
| Antiplatelets | 1.40 (1.15–1.70)*** | 1.36 (1.11–1.66)** | 1.07 (0.86–1.34) | |
| in AF | 2.6 (1.81–3.75)*** | 2.21 (1.52–3.22)*** | 1.47 (0.97–2.23) | |
| 2-years post-stroke | in non-AF | 1.09 (0.85–1.40) | 1.07 (0.83–1.39) | 0.93 (0.71–1.26) |
| BPLM | 0.59 (0.49–0.72)*** | 0.61 (0.50–0.75)*** | 0.51 (0.41–0.63)*** | |
| Statins | 0.48 (0.39–0.59)*** | 0.53 (0.43–0.66)*** | 0.52 (0.42–0.64)*** | |
| Anticoagulants in AF | 0.29 (0.19–0.45)*** | 0.33 (0.21–0.51)*** | 0.34 (0.22–0.53)*** | |
| Antiplatelets | 1.40 (1.08–1.83)* | 1.31 (0.99–1.72)* | 1.03 (0.76–1.38) | |
| in AF | 3.73 (2.19–6.36)*** | 3.28 (1.89–5.66)*** | 2.15 (1.15–4.00)* | |
| 3-years post-stroke | in non-AF | 1.02 (0.74–1.41) | 0.94 (0.68–1.31) | 0.80 (0.59–1.13) |
| BPLM | 0.57 (0.43–0.75)*** | 0.57 (0.43–0.75)*** | 0.46 (0.34–0.62)*** | |
| Statins | 0.35 (0.26–0.47)*** | 0.39 (0.29–0.54)*** | 0.37 (0.27–0.50)*** | |
| Anticoagulants in AF | 0.32 (0.17–0.59)*** | 0.35 (0.19–0.67)*** | 0.35 (0.18–0.68)** |
Results are presented as odds ratio (ORs) with 95% CI. Only survivors are included in the analyses. AF, atrial fibrillation; BPLM, blood pressure lowering medication. For 2- and 3-years post-stroke: strokes after 31-Dec-2013 and 31-Dec-2012 respectively are excluded due to the lack of follow-up data. Model 1 is adjusted for age and sex. Model 2 is adjusted for age, sex, nursing home placement at discharge. For antiplatelets, model 3 is adjusted for age, sex, nursing home placement at discharge, history of femur fracture, Charlson comorbidity index, and anticoagulants, for BPLM and statins, model 3 is adjusted for age, sex, nursing home placement at discharge, history of femur fracture, Charlson comorbidity index, and history of hemorrhagic stroke, while for anticoagulants, model 3 is adjusted for age, sex, nursing home placement at discharge, history of femur fracture, Charlson comorbidity index, and prior hemorrhagic stroke or history of any bleeding. *p < 0.05, **p < 0.01, ***p≤0.001.